CDK4 and breast carcinoma: Fortunately, the expression of androgen receptor (AR) is positively correlated with RB, which promotes cyclin D activation (103, 104), suggesting that CDK4/6 inhibitors have great potential in the treatment of HER2-negative breast cancer with AR-positive.